Back to journals
Academic JournalOpen Access

Therapeutic Advances in Psychopharmacology

20 Papers Indexed in Blossom

Published Papers

Open Accessmeta

Psychedelic therapy and postpartum depression: priorities and prospects

This review (2026) considers serotonergic psychedelic therapy as a potential treatment for postpartum depression, highlighting early encouraging findings but stressing that its efficacy and safety are not yet established. It also examines the biological pathways involved in postpartum depression and calls for tailored, long-term studies that account for the unique needs and risks of the postpartum period.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Thuery, G., Crossen, F., Mc Loone, D., Hinds, C., Duffy, R., Jairaj, C., Harkin, A., Kelly, J. R.
Open Accessindividual

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

In an open‑label 8‑week pilot trial, thematic analysis of interviews with 17 people with major depressive disorder found that many participants reported enhanced self‑determination, increased connectedness, clearer cognitive processing and improved emotional well‑being that they linked to reduced depressive symptoms. However, responses were heterogeneous—some reported negative effects or no benefit—and the open‑label design without a placebo control limits causal conclusions and emphasises the need for careful dosing and realistic expectations.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L., Forsyth, A., Evans, W., Hoeh, N. R., Sundram, F., Menkes, D., Muthukumaraswamy, S., Reynolds, L.
Open Accessindividual

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

An open‑label pilot trial of two 25 mg psilocybin sessions with preparatory and integration psychotherapy for treatment‑resistant depression produced a clinically meaningful reduction in self‑rated depressive symptoms at three weeks (Hedges’ g = −1.27) that was maintained at 20 weeks, although individual responses varied (two sustained responders, three relapses, two non‑responders). Exploratory analyses linked pre‑dosing mindset, spiritual experiences and perceptual shifts to outcome trajectories, with adverse events consistent with prior studies and no serious adverse events.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Meikle, S., Carter, O., Liknaitzky, P., Johansen, L., Iyer, R., Strauss, N., Williams, M., Castle, D., Rossell, S. L., Ids, O.
Open Accessmeta

History repeating: guidelines to address common problems in psychedelic science

The paper identifies ten key methodological and inferential challenges in contemporary psychedelic research that undermine internal, external, construct and statistical validity and often co‑occur, casting doubt on claims about efficacy and safety. It groups these problems by ease of resolution and provides a roadmap and practical checklist for researchers, journalists, funders and policymakers to improve rigour and better assess whether current optimism about therapeutic potential is warranted.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Van Elk, M., Fried, E. I.
Open Accessindividual

Classic psychedelics, health behavior, and physical health

In a US-representative sample (N = 2,822), lifetime use of classic psychedelics was associated with healthier tobacco- and diet-related behaviours, and among users greater psychological insight during their most insightful psychedelic experience predicted healthier exercise habits, healthier BMI and better diet (with some alcohol-related improvements). Although causality cannot be inferred, the results suggest psychological insight from classic psychedelic experiences may facilitate positive health-behaviour change, particularly for weight management.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., Goldberg, S. B.
Open Accessmeta

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

This meta-analysis (2021) assessed the literature regarding the possibilities of using ketamine to treat anxiety disorders. Six RCTs investigating various disorders were included. Ketamine was associated with treatment response for social anxiety disorder but not for PTSD. Doses of >0.5 mg/kg were associated with a greater reduction in scores of anxiety and these anxiolytic effects could be sustained.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Whittaker, E., Dadabayev, A. R., Joshi, S. A., Glue, P.

Quick Facts

Papers Indexed
20
h-Index
46
Open Access
Yes
Publisher
SAGE Publications
Country
United Kingdom
Website
Visit